CClinicalTrials.gg
CompletedNCT01185470Updated Apr 24, 2017

The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain

A Phase 2/3 interventional study of Implantation of Morphine Sulfate delivering programmable pump in Cancers and Chronic Pain, sponsored by Medallion Therapeutics, Inc.. Completed at 9 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2017-04-24.

Sponsored by Medallion Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

  • The objectives of this study are to confirm the medication delivery accuracy of the Infusion System, LLC Implantable Drug Delivery System (IDDS) with Patient Controlled Analgesia for intrathecal delivery of morphine sulfate for pain control, and to determine the safety profile of the system with PCA for intrathecal delivery of morphine sulfate for pain control.
02

Conditions studied

  • Cancers
  • Chronic Pain

Browse trials for

Keywords

  • Chronic pain
  • Morphine Sufate
  • Intrathecal
  • Implantable drug delivery pumps
03

In context

Chronic Pain

2,930 studies on the registry are indexed under Chronic Pain; 701 are open to participants now.

This study's enrollment of 75 is above the median of 60 across 2,161 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

This is the only study on the registry with Medallion Therapeutics, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Subject must be at least 21 years of age.
  2. Subject must have experienced chronic pain for at least 6 months.
  3. Subject must not presently be on intrathecal therapy but must be considered a candidate for intrathecal analgesia by his pain specialist; or, a subject already on intrathecal therapy must be in need of a replacement intrathecal pump and catheter.
  4. Subject must be capable of giving informed consent.
  5. Subjects who agree to sign a Pain Treatment Agreement (Narcotic Contract) limiting narcotic prescriptions to the study physician.
  6. Subjects who agree to periodic drug testing.
  7. Subject must be capable and willing to follow all study-related procedures, including returning for monthly refills.
  8. Subject must be cognitively intact and, in the opinion of the Investigator, capable of using the Patient Remote.
  9. Subject who is not already successfully treated with intrathecal analgesic therapy must be responsive to a trial of intrathecal or epidural morphine.
  10. Female subjects of child-bearing potential must agree to use a medically acceptable and effective double-barrier method of birth control.
  11. Documented failure to respond to less invasive methods of pain control (such as physical or behavioral modifications).
  12. Ineffective pain control with single or multiple systemic analgesic treatments (oral, rectal, IV or transdermal) or had intolerable side effects.
  13. Cancer pain requiring strong opioids or non-malignant pain with average Visual Analog Scale (VAS) score of ≥ 4/10.
  14. Subjects who can receive an MRI.
  15. Subjects must be able to hear and respond to audible alarms or agree to have a support person available who is able to hear and respond to audible alarms.

Exclusion criteria

Exclusion Criteria:

  1. Subject is a female who is pregnant or is planning a pregnancy.
  2. Subject is a nursing mother.
  3. Subject has at the site chosen for implantation a skin condition that would prevent the implantation procedure.
  4. Subject has participated in an investigational drug or device trial within 4 weeks prior to enrollment.
  5. Subject has any known or suspected allergy to morphine or to the materials of the infusion pump or intrathecal catheter.
  6. Subject shows signs of active, systemic infection.
  7. Subject has a known central nervous system contraindication to intrathecal therapy, including but not limited to severe spinal canal stenosis or spinal cord compression.
  8. Subject has a body size that is insufficient to accept the bulk and weight of the pump.
  9. Subject is allergic to morphine sulfate, or for whom morphine sulfate is contraindicated.
  10. Subject has a condition requiring diathermy procedures.
  11. Subject has a life expectancy of less than 9 months.
  12. Subject cannot independently comprehend and participate in the required assessments, including responding to the QOL, BPI, ODI and PGIC measurement tools.
  13. Subject is not considered to be medically or psychologically appropriate for pump implantation.
  14. Subject has a urine drug screen result which indicates the use of prescription drugs or controlled substances not on the order of a physician.
  15. Subjects with an ASA Physical Status >IV.
  16. Subjects with a history of spinal instability, or grade II spondylolisthesis or greater.
  17. Previously implanted subjects with spinal MRI findings of inflammatory mass prior to the implantation procedures.
  18. Subjects who are unable or unwilling to return to all of the required follow-up visits.
  19. Subjects who are unwilling to sign the informed consent.
  20. Subjects who are exposed to high-current industrial equipment (i.e. electricians or electrical engineers) or regularly exposed to MRI equipment (i.e. MRI technicians, MRI engineers and MRI clinicians).
  21. Subjects with active implanted devices such as pacemakers, defibrillators, cochlear implants and neurostimulators or other medical device use that can interfere with the function of the implanted intrathecal pump.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Subjects with Implantable pump

    Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .

    Device: Implantation of Morphine Sulfate delivering programmable pump

Interventions

  • DeviceImplantation of Morphine Sulfate delivering programmable pump

    Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.

06

What researchers measure

Primary outcomes

  1. • Mean medication delivery accuracy.

    Medication delivery accuracy will be evaluated at each of six (6) refills.

    Time frame: 6 months

Secondary outcomes

  1. • Tabulation of Adverse Events

    Time frame: 12 months

  2. Concomitant Medications, Physical and Neurological Exam, Inflammatory Masses, Vital Signs, Incidence of Inflammatory Masses, Summary of COWS

    Tabulation of Concomitant Medications, Tabulation of Physical and Neurological, Exam, Summary of Vital Signs, Incidence of Inflammatory Masses, Summary of COWS

    Time frame: 6 months

07

Study locations

9 sites
  • Center for Pain & Supportive Care
    Scottsdale, Arizona 85258, United States
  • Coastal Pain Research
    Carlsbad, California 92009, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • Neurovations
    Napa, California 94558, United States
  • Millenium Pain Center
    Bloomington, Illinois 61701, United States
  • Global Scientific Innovations, LLC
    Evansville, Indiana 47714, United States
  • Center for Pain Management
    Saint Louis, Missouri 63109, United States
  • The Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Pain Research of Oregon
    Eugene, Oregon 97401, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01185470
Lead sponsor
Medallion Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2010
Start date
Feb 2011
Primary completion
Jan 2015
Completion
Jul 2016
Last update
Apr 24, 2017

Study contacts

Richard Rauck, MD
principal investigator · The Center for Clinical Research

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion